🇺🇸 FDA
Patent

US 7220730

Cancer specific radiolabeled conjugates regulated by the cell cycle for the treatment and diagnosis of cancer

granted A61KA61K51/0491A61K51/0493

Quick answer

US patent 7220730 (Cancer specific radiolabeled conjugates regulated by the cell cycle for the treatment and diagnosis of cancer) held by BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA expires Mon May 17 2027 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
Grant date
Tue May 22 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 17 2027 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K51/0491, A61K51/0493